Medical Coding & Billing Guidelines for GLP-1 Medications
What Coders Need to Know About Coverage, Documentation, and Compliance
Glucagon-like peptide-1 (GLP-1) receptor agonists are now some of the most commonly prescribed medications in the U.S. Their effectiveness in treating type 2 diabetes and, more recently, obesity drives this growth. As a result, payer scrutiny is increasing too. For medical coding GLP-1 medications, accurate coding, documentation, and payer compliance are essential to avoid denials, audits, and recoupments.
This guide breaks down the coding and billing rules for GLP-1 medications. In addition, it provides practical tips for clean claims and compliant reimbursement.
What Are GLP-1 Medications?
GLP-1 receptor agonists mimic the incretin hormone GLP-1. In other words, they stimulate insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety.
Common GLP-1 medications include:
-
Semaglutide (Ozempic®, Wegovy®)
-
Liraglutide (Victoza®, Saxenda®)
-
Dulaglutide (Trulicity®)
-
Tirzepatide (Mounjaro®, Zepbound®)
-
Exenatide (Byetta®, Bydureon®)
Providers prescribe these drugs for type 2 diabetes mellitus and for chronic weight management when the drug is FDA approved for obesity.
Diagnosis Coding: Medical Necessity Is Everything
Diagnosis coding drives coverage for GLP-1 medications. For this reason, payers closely monitor off-label use.
Common ICD-10-CM Codes
Type 2 diabetes
-
E11.9 – Type 2 diabetes mellitus without complications
-
E11.65 – Type 2 diabetes mellitus with hyperglycemia
-
E11.8 – Type 2 diabetes mellitus with unspecified complications
Obesity and weight management
-
E66.9 – Obesity, unspecified
-
E66.01 – Morbid (severe) obesity due to excess calories
-
Z68.30–Z68.45 – BMI codes (required by many payers)
Prediabetes (often not covered for GLP-1 medications)
-
R73.03 – Prediabetes
Key Coding Tip
Most payers cover GLP-1 medications only for FDA-approved indications. Also, pharmacy benefits often exclude weight-loss drugs unless the employer plan opts in.
HCPCS Coding for GLP-1 Medications
When a clinic administers a GLP-1 drug in a clinical setting rather than through a retail pharmacy, coders may bill HCPCS J codes. For example, use J3490 (unclassified drugs) when no permanent code exists, or J3590 (unclassified biologics) when appropriate.
However, payers process many GLP-1 drugs under a pharmacy benefit rather than a medical benefit. In those cases, the claim goes through the patient’s pharmacy plan, not on a CMS-1500 or UB-04.
Key Coding Tip
Always verify whether the drug falls under the medical benefit (the buy and bill model) or the pharmacy benefit (a retail or specialty pharmacy).
CPT Coding for GLP-1 Related Visits
Providers commonly tie GLP-1 prescriptions to E/M visits, obesity counseling, or diabetes management.
Common CPT and HCPCS Codes
Office visits: 99202 through 99205 for new patients and 99211 through 99215 for established patients.
Obesity counseling: 99401 through 99404 for preventive counseling with commercial payers, and G0447 for face-to-face obesity counseling with Medicare.
Diabetes self-management training (DSMT): G0108 for individual sessions and G0109 for group sessions.
Prior Authorization and Payer Policy Requirements
Most payers require prior authorization (PA) for GLP-1 medications. Typically, PA requires a confirmed diagnosis of type 2 diabetes or obesity and a documented BMI, often 30 or higher, or 27 or higher with comorbidities. Payers also look for failed trials of other medications, lifestyle modification attempts, and recent A1C values for diabetes.
Documentation Must Include
-
Height and weight with calculated BMI
-
Diagnosis supporting medical necessity
-
Treatment plan
-
Follow-up and monitoring plan
Compliance and Audit Risk
GLP-1 medications are a high risk audit target. Utilization is growing rapidly, the drugs are expensive, and demand for weight loss drives off-label prescribing.
Common audit issues include incorrect diagnosis codes, missing BMI documentation, and a lack of medical necessity. Auditors also flag weight-loss drugs billed to Medicare and inappropriate use of unclassified J codes.
Medicare Coverage Rules
Medicare Part D has historically excluded drugs used only for weight loss, even when the FDA approves them for obesity. However, Medicare does cover GLP-1 medications for diabetes, such as Ozempic and Mounjaro. Medicare coverage rules for these drugs are changing, so always verify current CMS policy before you bill.
Coding Best Practices for GLP-1 Claims
First, always verify payer coverage policies and confirm the FDA-approved indication. Next, use the most specific ICD-10-CM code and include BMI codes when the payer requires them. In addition, make sure the documentation supports medical necessity, and confirm whether the drug falls under the pharmacy or medical benefit. Avoid unclassified J codes unless they are required. Finally, track prior authorization approvals, document patient counseling and monitoring, and watch for Medicare weight-loss exclusions.
Denial Prevention Checklist
Before you submit GLP-1 related claims, confirm the following:
-
Correct diagnosis code selection
-
BMI documented and coded
-
PA approval on file
-
Proper benefit type (pharmacy vs medical)
-
E/M level supported by documentation
-
Drug coverage confirmed by payer
GLP-1 medications are transforming diabetes and obesity care. However, they also bring complex billing and compliance challenges. For medical coders, success depends on accurate diagnosis selection, payer policy knowledge, prior authorization tracking, and airtight documentation.
As payer oversight increases, GLP-1 coding will remain a high impact, high risk area. Therefore, it requires careful attention to detail and constant policy updates.
Related Resources
Medical Coding Obesity
Medical Coding Bariatric Surgery
Medical Coding Diabetes
Diabetes Drugs And Weight Loss